Healthcare Finance News January 31, 2024
Paxlovid prescribed after March 8 will have a new designation not linked to emergency use authorization.
The Food and Drug Administration has set March 8 as the end of its emergency use authorization (EUA) for Paxlovid for adult patients, the agency has said this week. The medication is given to those considered high risk for progression to severe COVID-19, including hospitalization or death.
In May 2023, FDA approved Pfizer’s new drug application (NDA) for Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Now, Paxlovid currently in U.S. distribution will remain authorized for use through the labeled or extended expiration date, or through March 8, whichever is earlier.
However, the Paxlovid EUA will continue to authorize emergency use of the...
Today's Sponsors
Today's Sponsor